Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Elevated concentrations of serum MMA among participants with decreased cognitive performance. by Yige Liu (11940344)

Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

Lymphocytes decreased in mouse pneumonia model. by Qi Xu (134661)

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. by Hakim Ben Abdallah (14578241)

Cronbach’s alpha and means the stigma of Suicide Scale Short Form (SOSS-SF). by Orrin D. Ware (14829115)

Line graph showing the increase or decrease in the average number of bee swarms caught over the past three years (Mean  by Beatrice T. Nganso (4114768)

Boxplot comparing Ct values for HD in flies and clothes. by Philippe Ndzomo (17706039)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…</p> <p>Results showed that infected individuals had reduced baseline expression of antiviral factors and a diminished response to stimulation with a TLR7/8 agonist (CL097), compared to healthy individuals. A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …”

Evolution of mean values of posttraumatic stress symptomatology according to sociodemographic and occupational variables from baseline to 12-month. by Beatriz Arregui-Gallego (21553735)

Subjects:

TSLPR deficient mice show decreased AHR upon HDM exposure. by Latifa Koussih (326043)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects: